At a glance
- Originator Aventis
- Class Antiulcers
- Mechanism of Action Cholecystokinin B receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Peptic ulcer
Most Recent Events
- 08 Dec 1994 Discontinued-Preclinical for Peptic ulcer in France (Unknown route)